Show simple item record

dc.contributor.authorReck, Men
dc.contributor.authorThomas, Men
dc.contributor.authorKropf-Sanchen, Cen
dc.contributor.authorMezger, Jen
dc.contributor.authorSocinski, M Aen
dc.contributor.authorDepenbrock, Hen
dc.contributor.authorSoldatenkova, Ven
dc.contributor.authorBrown, Jen
dc.contributor.authorKrause, Ten
dc.contributor.authorThatcher, Nicken
dc.date.accessioned2016-12-16T15:35:35Z
dc.date.available2016-12-16T15:35:35Z
dc.date.issued2016
dc.identifier.citationNecitumumab plus gemcitabine and cisplatin as first-line therapy in patients with stage IV EGFR- expressing squamous non-small-cell lung cancer: German subgroup data from an open-label, randomized controlled phase 3 study (SQUIRE). 2016, 39(9): 539-47 Oncol Res Treaten
dc.identifier.issn2296-5262
dc.identifier.pmid27614872
dc.identifier.doi10.1159/000448085
dc.identifier.urihttp://hdl.handle.net/10541/620051
dc.description.abstractIn the SQUIRE study, adding the anti-epidermal growth factor receptor (EGFR) IgG1 antibody necitumumab to first-line gemcitabine and cisplatin (GC + N) in advanced squamous non-small-cell lung cancer (sqNSCLC) significantly improved overall survival (OS); the safety profile was acceptable. We explored data for the German subpopulation (N = 96) of SQUIRE patients with EGFR-expressing tumors.
dc.language.isoenen
dc.rightsArchived with thanks to Oncology research and treatmenten
dc.titleNecitumumab plus gemcitabine and cisplatin as first-line therapy in patients with stage IV EGFR- expressing squamous non-small-cell lung cancer: German subgroup data from an open-label, randomized controlled phase 3 study (SQUIRE).en
dc.typeArticleen
dc.identifier.journalOncology research and treatmenten
refterms.dateFOA2018-12-17T14:46:13Z
html.description.abstractIn the SQUIRE study, adding the anti-epidermal growth factor receptor (EGFR) IgG1 antibody necitumumab to first-line gemcitabine and cisplatin (GC + N) in advanced squamous non-small-cell lung cancer (sqNSCLC) significantly improved overall survival (OS); the safety profile was acceptable. We explored data for the German subpopulation (N = 96) of SQUIRE patients with EGFR-expressing tumors.


Files in this item

Thumbnail
Name:
2016 necitumumab.pdf
Size:
578.3Kb
Format:
PDF
Description:
Full text, Open Access Article

This item appears in the following Collection(s)

Show simple item record